ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT OCTOBER 2026

Zinzino Group revenue rose 1% year over year in October to SEK 328.7 million, including SEK 325.1 million from sales markets and SEK 3.6 million in Faun Pharma external sales, up 33%. Revenue for January–October 2026 increased 19% to SEK 3,128.0 million from SEK 2,628.2 million a year earlier.

Analysis

The key signal is the gap between strong year-to-date expansion and near-flat latest-month growth: it raises the risk that the growth rate is normalizing, but one month cannot establish a trend. If this persists, the market may reassess the durability of the growth premium before annual results show up in earnings. Faun Pharma’s external-sales growth is unlikely to offset or materially change the consolidated read-through at its reported scale; the larger question is whether the core sales markets regain momentum. The release does not provide the regional breakdown implied by its table header, nor gross margin, currency effects, or cash conversion, so the quality and source of growth remain unverified. Immediate reaction may be muted; over the next 1–3 months, subsequent monthly sales updates and any guidance commentary are the main catalysts. Over 6–18 months, sustained low growth would matter more if accompanied by weaker profitability or working-capital conversion. The mildly positive sentiment may underweight the deceleration risk, but without valuation, expectations, or profitability data there is no grounded basis for a directional position.

Key Decisions for Investors

• Do not chase the positive year-to-date growth signal on this release alone; treat ZZ.B as a watch rather than a fresh long until the next monthly update clarifies whether the latest slowdown is isolated.
• Verify the missing regional data, constant-currency growth, gross-margin trend, and operating cash conversion before underwriting the durability of growth; the supplied table header and article do not provide enough detail to distinguish mix or market-specific weakness.
• Escalate to a more cautious stance if the next one or two comparable monthly updates remain flat or turn negative, especially alongside weaker margin or cash conversion; that combination would strengthen the case for growth-multiple compression.
• The slowdown thesis is falsified by a clear reacceleration in comparable monthly sales, supported by broad-based regional contribution and stable profitability rather than a narrow or low-quality source of growth.